New pharmaceutical products face many potential hurdles to commercial success including regulatory approval, national and regional market access, and physician and patient acceptance and uptake, to name a few. Each stage of the development cycle involves an ever-widening group of stakeholders. Securing the buy-in of these influential external stakeholders requires pharmaceutical companies to look inward and encourage cross-functional collaboration and the ability to engage early, and often, along the path to launch and beyond. To read more, click the link below.
Navigating JCA for Orphan Medicinal Products: From scope simulation to pragmatic evidence generation for optimal patient access
The EU’s JCA framework is intended to streamline clinical evaluations and create a more consistent foundation for health technology assessments (HTAs) across...